Everolimus
- PDF / 169,217 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 85 Downloads / 115 Views
1 S
Various toxicities: 6 case reports In a study of 21 patients, 6 patients [ages and sexes not stated] were described, who developed hyperlipidaemia, enterocolitis, dermatitis, bacteraemia, hand-foot syndrome or Epstein-Barr virus infection during treatment with everolimus as a rescue therapy [duration of treatment to reactions onsets not stated]. The patients, who had unspecified disease, underwent living donor liver transplantation. Subsequently, the patients started receiving oral everolimus 0.125mg two times a day as a rescue treatment. However, the patients developed hyperlipidaemia (1 patient), enterocolitis (1 patient), dermatitis (1 patient), bacteraemia (1 patient), hand-foot syndrome (1 patient) and Epstein-Barr virus infection (1 patient) as adverse effects of everolimus. Therefore, therapy with everolimus was discontinued, leading to resolution of all the adverse effects. Ueno T, et al. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation. Transplantation Proceedings 52: 1829-1832, No. 6, 803501092 Aug 2020. Available from: URL: http://doi.org/10.1016/j.transproceed.2020.01.159
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
